



175 4/18/02

RECEIVED
APR 19 2002

TECH CENTER 1000/2900

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Substitute for form 1449A/PTO			
		Complete if Known			
		Application Number	09/975,800		
		Filing Date	October 11, 2001		
		First named Inventor	Kinam Park		
		Group Art Unit	1619		
Sheet	1	of	1	Examiner Name	
				Attorney Docket Number	368-014

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Document		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code2			
J		6,287,588	B1	Shih et al.	09-11-2001	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office3	Number4	Kind Code5			
J		WO	97/49387	A1	G.D.Searle&Co.	12-31-1997	
		WO	96/40285	A1	IMARx Pharmaceutial	12-19-1996	

Examiner Signature		Date Considered	3/04
--------------------	--	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO



(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	09/975,800
---------------------------	------------

Filing Date	October 11, 2001
--------------------	------------------

First named Inventor	Kinam Park
----------------------	------------

Group Art Unit

Examiner Name

Attorney Docket Number	368-014
------------------------	---------

[illegible][illegible]

Examiner Signature		Date Considered	3/04
-----------------------	---	--------------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/975,800
Filing Date	October 11, 2001
First named Inventor	Kinam Park
Group Art Unit	
Examiner Name	
Attorney Docket Number	368-014

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
J		NICOLAOU, K. et al. "Design, synthesis and biological activity of protaxols," Nature, 1993, 364: 464-466.	
J		PENDRI, A., et al. "Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug," Anti-Cancer Drug Design, 1998, 13: 387-395.	
		TAVARE, N. et al. "Solubilities of 6-aminopenicillanic acid and phenoxyacetic acid in hydrotrope solutions," J. Chem. Eng. Data, 1996, 41: 1196-1202.	
		MULLER, B. et al. "Effect of hydrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on the pharmacokinetics of the drugs," J. Pharm. Sci., 1991, 80: 599-604.	
		GRAZIANO, G. "On the solvent isotope effect in hydrophobic hydration," J. Phys. Chem. B, 2000, 104: 9249-9254.	
		KUMAR, M. et al. "Effect of hydrotropes on solubility and mass transfer coefficient of methyl salicylate," J. Chem. Eng. Data, 2000, 45: 419-423.	
		SRINIVAS, V., et al. "When does the switch from hydrotropy to micellar behavior occur?" Langmuir, 1998, 14: 6658-6661.	
		DHARA, D. et al., "Effect of hydrotropes on the volume phase transition in poly(N-isopropylacrylamide) hydrogel," Langmuir, 1999, 15: 930-935.	
		SALEH, A., et al., "Solubilization of water by hydrotropic salts," J. Pharm. Sci., 1986, 75: 644-647.	
		COFFMAN, R., et al., "Effect of nicotinamide and urea on the solubility of riboflavin in various solvents," J. Pharm. Sci., 1996, 85: 951-954.	
		SERAJUDDIN, A. "Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs," J. Pharm. Sci., 1999, 88: 1058-1066.	
		ALKAN-ONYUKSEL, H. et al. "A mixed micellar formulation suitable for the parenteral administration of taxol," Pharm. Res., 1994, 11: 206-212.	
		SHARMA, A. et al. "Novel taxol formulations: preparation and characterization of taxol-containing liposomes," Pharm. Res., 1994, 11: 889-896.	
J		MANI, S., et al. "Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)," Cancer Chemother. Pharm., 1998, 42: 84-87.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Complete if Known

Application Number	09/975,800
--------------------	------------

Filing Date	October 11, 2001
--------------------	------------------

First named Inventor	Kinam Park
-----------------------------	------------

Group Art Unit

Examiner Name

Attorney Docket Number	368-014
------------------------	---------

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
--------------------	------------	---

T6

FORD, J. "The current status of solid dispersions," *Pharm. Acta Helv.*, 1986, 61: 69-88.

LEUNG, S. et al., "Polymeric micellar paclitaxel phosphorylates bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors," *The Prostate*, 2000, 44: 156-163.

CHIOU, W., et al., "Pharmaceutical Applications of Solid Dispersion Systems," *J. Pharm. Sci.*, 1971, 60: 1281-1302.

FLOYD, A. G. et al. "7. Injectable emulsions and suspensions." Pharmaceutical Dosage Forms: Disperse Systems. 1998, pp. 261-318, Vol. 2, Marcel Dekker, Inc., New York, NY

MACHERAS, P., et al., "4. Supply of the gastrointestinal fluids with drug," Biopharmaceutics of Orally Administered Drugs, 1995, pp. 35-87, Ellis Horwood, New York, NY.

LOBENBERG, R., et al., "9. Solubility as a limiting factor to drug absorption," *Oral Drug Absorption. Prediction and Assessment*, pp. 137-153, Marcel Dekker, Inc., New York, NY

MULLER, R. H. et al., "9. Nanosuspensions," Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs, 1998, pp. 149-174, Medpharm Scientific Publ., Stuttgart, Germany

HABIB, M. J., et al. "2. Fundamentals of solid dispersions," Pharmaceutical Solid Dispersion Technology, 2001, pp. 7-35, Technomic Pub. Co., Inc., Lancaster, PA

MARTIN, A., et al., Physical Pharmacy. Physical Chemical Principles in the Pharmaceutical Sciences, 1993, pp.272-273, 4thed, Lea & Febiger, Philadelphia, PA

YALKOWSKY, S., Solubility & Solubilization in Aqueous Media, 1999, p. 429, ACS Publ., Washington, DC

Examiner
Signature

Date
Considered

3/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**